At the conference, SciBase presented its product Nevisense – an AI-powered detection enhancement technology that improves the ability for early detection of melanoma at point of care. Melanomas have a fast growth rate and a delay in treatment may mean the difference between life and death. Early detection is the key to survival as melanoma has a 99% cure rate if caught in the earliest stages. Attendees had the opportunity to learn about Nevisense in the scientific sessions where Nevisense was presented and gain valuable insight on how to improve patient outcomes by integrating Nevisense into their clinical practices. The interest for Nevisense was great and we had a well-attended booth resulting in many new installation opportunities for SciBase in the US. „This congress provided SciBase with a platform to engage with top dermatology professionals in the US at the same time as we had the opportunity to present our AI-driven technology for enhancing melanoma detection at point of care. “ says Pia Renaudin, CEO of SciBase. For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases The post Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami first appeared on Scibase.
Skin barrier function has been implicated as a driving factor in many dermatological disorders, including Atopic Dermatitis (AD). AD is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Additionally, skin barrier function is commonly assessed in the research and development of pharmaceutics and cosmetic products. The study was performed on healthy adults between 22 and 65 years of age and aimed at determining factors that influence the measurement results of both EIS and TEWL. The top-line results of the study indicated that: TEWL measurements were influenced by physical activity, body cream application, skin washing, and caffeine intake. EIS measurements were only influenced by body cream application and skin washing. EIS was not influenced by physical activity or caffeine intake. Both the abdomen and the volar forearm were identified as useful anatomical locations for EIS measurements. The authors concluded that EIS (Nevisense) can assess skin barrier function with less sensitivity to confounding lifestyle factors than TEWL. „For SciBase, these findings help to open up the cosmetic and pharmaceutical research markets for Nevisense, potentially as the new state-of-the-art tool for skin barrier assessment. This study strengthens the evidence that EIS is an established, robust technique for these researchers. We aim to provide the medical community with the best products possible in their research and management for dermatological disorders,“ says Pia Renaudin CEO, SciBase. The full results of the study have now been published in the scientific journal Annals of Dermatology and can be found here: https://anndermatol.org/DOIx.php?id=10.5021/ad.23.052 The study was carried out at Vrije Universiteit Brussel (VUB) in Belgium. For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Colerus, CFO, tel. +46703413472, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL first appeared on Scibase.
The research reports, analyst comments and interview videos will be published and made available on inderes.se, inderes.dk and inderes.fi with over 70,000 active members, as well as through Inderes‘ channels on social media and other investor platforms. The first analysis is planned to be carried out in the first quarter of 2024. Inderes welcomes all investors to discuss and ask questions from the analyst on forum.inderes.se once the research is published. The main purpose of the collaboration is to: 1) Increase investor awareness of SciBase 2) Help investors better understand SciBase 3) Create a communication channel between the investors and SciBase 4) Improve the price formation and liquidity of SciBase’s stock For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Colerus, CFO, tel. +46703413472, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases About Inderes Inderes connects investors and listed companies, with the aim of democratizing information in the financial markets. Inderes helps over 400 Nordic listed companies to better serve their shareholders. Inderes‘ Nordic community consists of over 70,000 active investors. The post SciBase initiates collaboration with Inderes for commissioned research first appeared on Scibase.
SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase’s future trajectory, and unveil an updated strategic outlook, and long-term strategic goals. The presentations will underscore the company’s focus on the USA and shed light on SciBase’s ongoing expansion into promising new markets. Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward. Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at the Mount Sinai Icahn School of MedicineDr. Rigel, a US-based and world-prominent dermatologist will talk about his experiences regarding the clinical benefits of SciBase products. Dr. Rigel has been a Dermatology leader for 30+ years, served as President of major associations such as AAD (American Academy of Dermatology), and Vice-President of the American Board of Dermatology for 13 years. A trusted advisor on national health policy, he testifies before Congress and the FDA, consulting for government and industry. As Scientific Co-Chair of Clinical Dermatology Conferences, he educates over 4000 colleagues annually. Maintaining practices in Manhattan and Dallas, Dr. Rigel specializes in Melanoma, Skin Cancer, and related issues. Internationally acclaimed, he delivers 1000+ lectures globally, is featured on CNN, Fox, ABC, and NBC, is quoted in major publications, and serves as the Team Dermatologist for the New York Yankees. With an MIT BS, MBA from MIT Sloan, and MD from George Washington University, he completed training at NYU and is a Clinical Professor at Mt. Sinai Icahn School of Medicine. Kathy Francisco, MBA, CPC, Founder and CEO Kathy established The Pinnacle Health Group in 1999 as a consulting group specializing in reimbursement for health care technologies, drugs, and biologics. For over 25 years, Pinnacle has been providing effective and appropriate reimbursement support for healthcare providers across the country. The Pinnacle team is comprised of certified coders, reimbursement specialists, and clinicians supporting clients with the development of strategic planning, economic positioning, financial analysis, payer coverage strategy, and tactical reimbursement positioning. In addition, daily support is offered to providers offering HIPAA-compliant prior authorization, appeals, and appropriate payment for procedures and technologies that are key to ongoing medically necessary patient care. Following the presentations, there will be an interactive session allowing participants to pose questions. The event will be digitally broadcast, starting at CET 14:00 and is expected to last until CET 15:30. A recording of the event will be made available on the SciBase website. Date: January 25, 2024 Time: CET 14:00 – 15:30 CET. Format: Digital. The presentations will be in English. Link to meeting : https://ir.financialhearings.com/scibase-cmd-2024 Welcome! For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Colerus, CFO, tel. +46703413472, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post Reminder: Welcome to SciBase Capital Markets Day 2024 first appeared on Scibase.
SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase’s future trajectory, and unveil an updated strategic outlook, and long-term strategic goals. The presentations will underscore the company’s focus on the USA and shed light on SciBase’s ongoing expansion into promising new markets. Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward. Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at the Mount Sinai Icahn School of MedicineDr. Rigel, a US-based and world-prominent dermatologist will talk about his experiences regarding the clinical benefits of SciBase products. Dr. Rigel has been a Dermatology leader for 30+ years, served as President of major associations such as AAD (American Academy of Dermatology), and Vice-President of the American Board of Dermatology for 13 years. A trusted advisor on national health policy, he testifies before Congress and the FDA, consulting for government and industry. As Scientific Co-Chair of Clinical Dermatology Conferences, he educates over 4000 colleagues annually. Maintaining practices in Manhattan and Dallas, Dr. Rigel specializes in Melanoma, Skin Cancer, and related issues. Internationally acclaimed, he delivers 1000+ lectures globally, is featured on CNN, Fox, ABC, and NBC, is quoted in major publications, and serves as the Team Dermatologist for the New York Yankees. With an MIT BS, MBA from MIT Sloan, and MD from George Washington University, he completed training at NYU and is a Clinical Professor at Mt. Sinai Icahn School of Medicine. Kathy Francisco, MBA, CPC, Founder and CEO Kathy established The Pinnacle Health Group in 1999 as a consulting group specializing in reimbursement for health care technologies, drugs, and biologics. For over 25 years, Pinnacle has been providing effective and appropriate reimbursement support for healthcare providers across the country. The Pinnacle team is comprised of certified coders, reimbursement specialists, and clinicians supporting clients with the development of strategic planning, economic positioning, financial analysis, payer coverage strategy, and tactical reimbursement positioning. In addition, daily support is offered to providers offering HIPAA-compliant prior authorization, appeals, and appropriate payment for procedures and technologies that are key to ongoing medically necessary patient care. Following the presentations, there will be an interactive session allowing participants to pose questions. The event will be digitally broadcast, starting at CET 14:00 and is expected to last until CET 15:30. A recording of the event will be made available on the SciBase website. Date: January 25, 2024 Time: CET 14:00 – 15:30 CET. Format: Digital. Additional information regarding participation and a link will be published later. The presentations will be in English. Welcome! For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Colerus, CFO, tel. +46703413472, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post Welcome to SciBase Capital Markets Day 2024 first appeared on Scibase.
SciBase has gone from being an innovation Company originating from the Karolinska Institute to a global company that supports physicians in their work by enabling early detection and prevention in skin cancer and other skin diseases. During SciBase’s capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase’s way forward, updated strategy and long-term goals. The presentations will focus on the USA as well as SciBase’s ongoing establishment in new promising markets. Several external speakers will participate in the event. A US-based and world prominent dermatologist will talk about his experiences regarding the clinical benefits with SciBase products. Pinnacle, an independent specialist company in the US reimbursement system, will explain the SciBase path towards reimbursement in the US. After the presentations, there will be an opportunity to ask questions. The event will be broadcasted digitally and will begin at CET 14:00 and is expected to last until CET 15:30. A recording of the event will be available on SciBase website. Date: January 25, 2024 Time: CET 14:00 – 15:30 CET. Format: Digital. Additional information regarding participation and a link will be published at a later date. The presentations will be in English. Welcome! For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: Colerus, CFO, tel. +46703413472, e-mail: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post SciBase capital markets day 2024 – save the date first appeared on Scibase.
„Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes,“ said Dr. Simon Madorsky, medical director and founder of the Skin Cancer and Reconstructive Surgery Center. Dr. Madorsky is also the CME Chair of the SCARS Foundation, dedicated to skin cancer research and physician education. „At SCARS Center, we are dedicated to providing our patients and physicians with the resources needed to understand, prevent, and cure skin cancers. We have long been at the forefront of innovation, and we look forward to furthering those capabilities with Nevisense. Early detection of skin cancers with advanced technology provides patients with the peace of mind they deserve during skin cancer checks,“ said Dr. Madorsky. „SciBase and the SCARS Center team are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes,“ said Pia Renaudin, CEO of SciBase. „We are continuing to broaden SciBase’s presence throughout the US, to further increase patient access to point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable“. For more information, please contact: Pia Renaudin, CEO SciBase Tel: +46 73 206 98 02 Email: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About the Skin Cancer and Reconstructive Surgery Center The Skin Cancer and Reconstructive Surgery Center is an all-encompassing skin cancer treatment facility dedicated to achieving skin cancer cure while maintaining the functionality and appearance of the face and body. The SCARS Center accepts referrals at any point in their skin cancer journey, frequently coordinating Mohs surgery and reconstructive surgery with local physicians for an improved patient experience. Their accredited onsite surgery center allows Mohs surgeons and reconstructive surgeons the ability to work together to provide skin cancer treatment in one convenient location. The surgery center includes two operating rooms, two recovery rooms, and a serene waiting area for patients‘ family members. The SCARS Center board certified anesthesiologists provide exceptional care in local, monitored anesthesia, and general anesthesia. About SciBase and NevisenseSciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection first appeared on Scibase.
„We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and treatment are critical for improving survival rates. We are committed to providing life-saving treatments to our patients and strive to deliver the highest level of care possible. For these reasons, we want to provide our patients with the most advanced technology that further supports our commitment to delivering the best care to our patients,“ said Dr. Dan Taheri, Medical Director and CEO of The Skin Cancer Institute Dermatology Group. „We are very pleased to announce our collaboration with the Skin and Cancer Institute. In addition to the early detection benefits for patients, the partnership means clinicians at several of their California offices will have access to state-of-the-art melanoma detection technology at point-of-care. For SciBase, this means we expand and establish a coast-to-coast reach that provides patients with access to early melanoma detection technology. It also helps introduce Nevisense to more US payers.“ said Pia Renaudin, Chief Executive Officer of SciBase. For more information, please contact: Pia Renaudin, CEO SciBase Tel: +46 73 206 98 02 Email: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase and NevisenseSciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases . The post SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California first appeared on Scibase.
Thomas Axelsson (Gell Group), Dharminder Chahal (VanHerk Group), Peter Elmvik (Stockholms Elbolag), Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 17, 2023. The Annual General Meeting of SciBase Holding AB (publ) will be held on May 17, 2024 in Stockholm. Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting. Stockholm, November 2, 2023 SciBase Holding AB (publ) For more information, please contact:Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67 Michael Colérus, CFO, phone +46 70 341 34 72 Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post Nomination Committee appointed for SciBase Holding’s Annual General Meeting in 2024 first appeared on Scibase.
Skin barrier research comprises one of the fastest-growing fields within the dermatology community, including the development of new therapeutics, testing cosmetics, and beauty products, testing other consumer goods, and the scientific investigation of diseases related to the skin barrier. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice and human skin samples. The top-line results of the study indicated that: EIS is a reliable biomarker/indicator of the skin barrier function in both ex vivo (lab research) and in vivo (human studies) models, with a higher sensitivity than trans-epidermal water loss (TEWL). EIS showed a significant correlation with protein biomarkers that are associated with inflammatory pathways. EIS further correlated with the expression of skin barrier-related genes. EIS is a fast and reliable tool for investigating skin barrier function in both ex vivo and in vivo models, with possible applications in dermatological and cosmetic studies. „We are very encouraged to see that EIS measurements could identify skin barrier impairment at such an early stage and with high sensitivity. EIS provides an increasingly useful tool for such evaluations“ said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research). „This publication represents a rewarding collaborative effort between several leading organizations in the skin barrier research space. We are proud of the technology underpinning the success of this project. Skin barrier research has grown rapidly to include diseases like eczema, psoriasis, allergic disorders, and many others. We believe that Nevisense has the potential to become the state-of-the-art research tool within the skin barrier space, and now we can expand this to include ex vivo, in vivo, and human studies,“ says Pia Renaudin, appointed Chief Executive Officer of SciBase. The full results of the study have now been published in the scientific journal Allergy Household laundry detergents disrupt barrier integrity and induce inflammation in mouse and human skin – Rinaldi – Allergy – Wiley Online Library. The study was carried out jointly from SIAF (CH), SciBase (SE), and Genoskin (FR), amongst others. For more information, please contact: Tord Lendau, Chairman of the Board Tel: +46 70 810 01 67Email: Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: About SciBase and NevisenseSciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases The post Nevisense detects skin barrier damage from skin models in research first appeared on Scibase.
